- Home
- MNPR vs MGRM Comparison
MNPR vs MGRM Comparison
Compare MNPR & MGRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- MGRM
- Stock Information
- Founded
- MNPR 2014
- MGRM 2016
- Country
- MNPR United States
- MGRM United States
- Employees
- MNPR N/A
- MGRM N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- MGRM Medical/Dental Instruments
- Sector
- MNPR Health Care
- MGRM Health Care
- Exchange
- MNPR Nasdaq
- MGRM Nasdaq
- Market Cap
- MNPR 248.8M
- MGRM 232.0M
- IPO Year
- MNPR 2019
- MGRM N/A
- Fundamental
- Price
- MNPR $66.64
- MGRM $5.77
- Analyst Decision
- MNPR Strong Buy
- MGRM Strong Buy
- Analyst Count
- MNPR 11
- MGRM 1
- Target Price
- MNPR $68.60
- MGRM $5.40
- AVG Volume (30 Days)
- MNPR 44.1K
- MGRM 95.0K
- Earning Date
- MNPR 11-07-2025
- MGRM 11-13-2025
- Dividend Yield
- MNPR N/A
- MGRM N/A
- EPS Growth
- MNPR N/A
- MGRM N/A
- EPS
- MNPR N/A
- MGRM N/A
- Revenue
- MNPR N/A
- MGRM N/A
- Revenue This Year
- MNPR N/A
- MGRM N/A
- Revenue Next Year
- MNPR N/A
- MGRM N/A
- P/E Ratio
- MNPR N/A
- MGRM N/A
- Revenue Growth
- MNPR N/A
- MGRM N/A
- 52 Week Low
- MNPR $3.90
- MGRM $1.92
- 52 Week High
- MNPR $68.18
- MGRM $6.02
- Technical
- Relative Strength Index (RSI)
- MNPR 80.24
- MGRM 59.95
- Support Level
- MNPR $42.51
- MGRM $5.67
- Resistance Level
- MNPR $45.78
- MGRM $5.89
- Average True Range (ATR)
- MNPR 4.36
- MGRM 0.14
- MACD
- MNPR 2.91
- MGRM -0.03
- Stochastic Oscillator
- MNPR 95.65
- MGRM 30.56
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.